Last Price$105.41.0%
Market Cap$21.6B
P/FCF LTM
18.4x
5Y avg
23.5x
Medical - Devices industry
median
(0.7x)
Stock quality & Intrinsic value
6/10
0.7% undervalued
Zimmer Biomet Holdings, Inc. P/FCF LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/FCF LTM | 44.1x | 18.3x | 21.8x | 25.2x | 11.1x | 23.3x | 10.0x | 11.1x | 11.8x | 17.8x | 21.5x | 32.3x | 16.5x | 14.4x | 12.6x | 26.0x | 31.1x | 18.3x | 22.0x | 29.5x |
Overvalued or undervalued?
Check the intrinsic value for ZBH
and see if it's the right time to invest.
Zimmer Biomet Holdings, Inc. (ZBH) P/FCF LTM comparison analysis
General
LTM P/FCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Zimmer Biomet Holdings, Inc.ZBH
19.1x
6.5%
253.2%
13.8%
Median Peer Set
53.3x
4.1%
72.0%
11.8%
Edwards Lifesciences CorporationEW
86.5x
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V.PHG
85.9x
(0.8%)
118.1%
(3.9%)
DexCom, Inc.DXCM
76.9x
11.3%
(1.4%)
14.3%
Insulet CorporationPODD
64.0x
30.0%
4,364.6%
12.2%
Boston Scientific CorporationBSX
63.4x
17.6%
16.7%
11.1%
Stryker CorporationSYK
43.2x
10.2%
(5.8%)
13.2%
Abbott LaboratoriesABT
38.2x
4.6%
134.5%
31.9%
STERIS plcSTE
29.2x
3.6%
257.9%
7.4%
Medtronic plcMDT
22.1x
3.6%
(2.1%)
11.4%
Align Technology, Inc.ALGN
21.8x
3.4%
26.0%
11.5%
ZBH key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 2,980.9 0.0% | 3,286.1 10.2% | 3,495.4 6.4% | 3,897.5 11.5% | 4,121.1 5.7% | 4,095.4 (0.6%) | 4,220.2 3.0% | 4,451.8 5.5% | 4,471.7 0.4% | 4,623.4 3.4% | 4,673.3 1.1% | 5,997.8 28.3% | 7,683.9 28.1% | 7,824.1 1.8% | 7,932.9 1.4% | 7,982.2 0.6% | 7,024.5 (12.0%) | 6,827.3 (2.8%) | 6,939.9 1.6% | 7,394.2 6.5% |
| Cost of Goods Sold (COGS) | 779.9 | 739.4 | 780.1 | 875.9 | 997.3 | 990.8 | 1,012.4 | 1,122.0 | 1,125.2 | 1,286.1 | 1,249.8 | 1,856.6 | 2,374.9 | 2,132.9 | 2,271.9 | 2,252.6 | 2,128.3 | 1,960.4 | 2,019.5 | 2,083.8 |
% margin | 2,201.0 73.8% | 2,546.7 77.5% | 2,715.3 77.7% | 3,021.6 77.5% | 3,123.8 75.8% | 3,104.6 75.8% | 3,207.8 76.0% | 3,329.8 74.8% | 3,346.5 74.8% | 3,337.3 72.2% | 3,423.5 73.3% | 4,141.2 69.0% | 5,309.0 69.1% | 5,691.2 72.7% | 5,661.0 71.4% | 5,729.6 71.8% | 4,896.2 69.7% | 4,866.9 71.3% | 4,920.4 70.9% | 5,310.4 71.8% |
| Operating Expenses | 1,356.7 | 1,435.1 | 1,544.0 | 1,868.8 | 1,965.3 | 1,937.5 | 2,052.4 | 2,230.5 | 2,032.7 | 2,038.0 | 2,010.8 | 2,901.6 | 3,864.4 | 3,945.2 | 4,513.8 | 4,459.8 | 4,198.3 | 3,861.5 | 3,728.3 | 4,032.7 |
| Research & Development Expenses (R&D) | 166.7 | 175.5 | 188.3 | 209.6 | 194.0 | 205.4 | 220.0 | 238.6 | 225.6 | 204.2 | 188.3 | 268.8 | 365.6 | 367.4 | 391.7 | 449.3 | 372.0 | 435.8 | 406.0 | 458.7 |
| Selling, General & Administrative Expenses (SG&A) | 1,190.0 | 1,259.6 | 1,355.7 | 1,489.7 | 1,702.3 | 1,732.1 | 1,832.4 | 1,834.1 | 1,807.1 | 1,833.8 | 1,822.5 | 2,284.2 | 2,932.9 | 2,973.9 | 3,379.3 | 3,343.8 | 3,177.8 | 2,843.4 | 2,761.7 | 2,838.9 |
% margin | 763.2 25.6% | 1,055.0 32.1% | 1,165.2 33.3% | 1,127.6 28.9% | 1,090.0 26.4% | 1,018.8 24.9% | 916.7 21.7% | 1,024.1 23.0% | 1,047.4 23.4% | 1,035.6 22.4% | 1,034.7 22.1% | 326.4 5.4% | 827.9 10.8% | 823.2 10.5% | 33.8 0.4% | 1,137.5 14.3% | 723.3 10.3% | 860.3 12.6% | 1,064.1 15.3% | 1,277.7 17.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.7 | 10.1 | 15.6 | 15.6 | 11.9 | 9.4 | 2.9 | 2.2 | 3.3 | 226.9 | 212.1 | 208.4 | 164.8 | 0.0 |
| Interest Expense | 194.0 | 128.4 | 8.9 | 216.4 | 31.8 | 20.6 | 60.2 | 45.2 | 72.9 | 70.1 | 63.1 | 286.6 | 357.9 | 327.5 | 292.6 | 226.9 | 212.0 | 208.4 | 164.8 | 201.2 |
| Pre-tax Income | 731.5 | 1,040.7 | 1,169.0 | 1,131.6 | 1,121.8 | 998.2 | 860.2 | 978.9 | 990.1 | 981.1 | 943.9 | 12.3 | 401.6 | 479.6 | (271.1) | 905.8 | (274.4) | 499.0 | 403.5 | 1,067.3 |
% effective tax rate | 189.6 25.9% | 307.3 29.5% | 334.0 28.6% | 357.9 31.6% | 272.3 24.3% | 280.8 28.1% | 263.3 30.6% | 218.9 22.4% | 237.2 24.0% | 221.9 22.6% | 224.9 23.8% | (36.6) (297.6%) | 100.0 24.9% | (1,359.6) (283.5%) | 108.2 (39.9%) | (225.7) (24.9%) | (137.0) 49.9% | 53.5 10.7% | 112.3 27.8% | 42.2 4.0% |
% margin | 541.8 18.2% | 732.5 22.3% | 834.5 23.9% | 773.2 19.8% | 848.6 20.6% | 717.4 17.5% | 596.9 14.1% | 760.8 17.1% | 755.0 16.9% | 761.0 16.5% | 720.1 15.4% | 49.7 0.8% | 302.9 3.9% | 1,839.6 23.5% | (379.2) (4.8%) | 1,131.6 14.2% | (137.4) (2.0%) | 401.6 5.9% | 231.4 3.3% | 1,024.0 13.8% |
| EPS | 2.22 | 2.96 | 3.43 | 3.28 | 3.73 | 3.34 | 2.98 | 4.06 | 4.32 | 4.49 | 4.26 | 0.27 | 1.51 | 9.11 | (1.86) | 5.52 | (0.66) | 1.93 | 1.39 | 4.91 |
| Diluted EPS | 2.19 | 2.93 | 3.40 | 3.26 | 3.72 | 3.32 | 2.97 | 4.03 | 4.29 | 4.43 | 4.19 | 0.26 | 1.50 | 9.03 | (1.86) | 5.47 | (0.66) | 1.91 | 1.38 | 4.88 |
% margin | 1,106.7 37.1% | 1,353.9 41.2% | 1,366.4 39.1% | 1,361.6 34.9% | 1,403.9 34.1% | 1,356.2 33.1% | 1,256.9 29.8% | 1,385.8 31.1% | 1,426.3 31.9% | 1,409.7 30.5% | 1,781.1 38.1% | 2,337.0 39.0% | 1,788.4 23.3% | 1,849.6 23.6% | 1,059.4 13.4% | 2,395.0 30.0% | 969.7 13.8% | 2,160.1 31.6% | 2,212.6 31.9% | 2,214.3 29.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Zimmer Biomet Holdings, Inc.'s P/FCF LTM?
As of today, Microsoft Corp's last 12-month P/FCF LTM is 18.4x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/FCF LTM for Zimmer Biomet Holdings, Inc. have been 23.1x over the past three years, and 24.6x over the past five years.
2) Is Zimmer Biomet Holdings, Inc.'s P/FCF LTM Good?
As of today, Zimmer Biomet Holdings, Inc.'s P/FCF LTM is 18.4x, which is higher than industry median of (0.7x). It indicates that Zimmer Biomet Holdings, Inc.'s P/FCF LTM is Bad.